Sanofi

Sanofi is a publicly traded French multinational pharmaceutical company founded in 1973, headquartered in Paris, France. The company trades on Euronext Paris under ticker SNY and reported FY2025 net sales of €43.63 billion, up 9.9 percent at constant exchange rates, with business EPS of €7.83, up 15.0 percent. Growth was driven by Dupixent (€15.7 billion in FY2025 sales, up 25.2 percent). Sanofi operates as a single Biopharma segment with approximately 74,846 employees worldwide. CEO Paul Hudson departed in February 2026, with Belén Garijo appointed as new CEO effective April 29, 2026.

Sanofi was founded in 1973 as a pharmaceutical subsidiary of Elf Aquitaine, a French oil and chemical company. The company began as a pharmaceutical manufacturer focused on developing and producing medicines. Sanofi's vision was to create innovative pharmaceutical solutions that would serve patients globally, establishing Sanofi as a pioneer in the pharmaceutical industry.

Throughout the late 20th and early 21st centuries, Sanofi expanded its product portfolio and became known for its commitment to pharmaceutical innovation and quality. The company established itself as one of the world's leading pharmaceutical manufacturers, with products serving diverse therapeutic areas. Sanofi became a trusted brand among healthcare professionals and patients.

In the late 20th century, Sanofi became a leader in diabetes care and cardiovascular disease treatment. The company expanded globally and acquired numerous pharmaceutical companies, establishing itself as a leader in multiple therapeutic areas. Between 2008 and 2010, under CEO Chris Viehbacher, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming patent cliffs and the growth of the consumer health market.

In recent decades, Sanofi has continued to focus on innovation in specialty pharmaceuticals and vaccines. The company has invested heavily in research and development and has become a leader in immunology, oncology, and vaccines. Sanofi remains one of the world's leading pharmaceutical companies with a diverse portfolio spanning multiple therapeutic areas. The company's transformation into an R&D-driven, AI-powered biopharmaceutical company represents its commitment to next-generation healthcare innovation.

In 2026, Sanofi underwent significant leadership changes as the Board of Directors decided not to renew CEO Paul Hudson's mandate. Hudson's last day as CEO was February 17, 2026, after six years of leadership during which he launched strategic initiatives and transformed the company. The Board appointed Belén Garijo as the new CEO, who will take up her duties on April 29, 2026, at the end of the company's Annual General Meeting. Garijo, who previously served as CEO of Merck KGaA and was the first woman to lead a DAX40 company in Germany, brings extensive experience from her 15 years at Sanofi and is expected to accelerate the implementation of Sanofi's strategy and strengthen R&D productivity and innovation capacity.

Sanofi has committed to environmental sustainability and leads an industry working group on biopharma life cycle assessment, demonstrating leadership in pharmaceutical environmental impact measurement. The company has set targets to reduce its environmental footprint across manufacturing operations and supply chain activities.

Sanofi reached an agreement with the US government in 2025 to lower medicine costs while strengthening innovation, balancing access to medicines with continued investment in research and development. This agreement reflects the company's commitment to addressing healthcare affordability while maintaining its innovation capacity.

The company is not a Certified B Corporation, and pharmaceutical companies are generally required to conduct animal testing for regulatory approval in most jurisdictions. Sanofi states it follows ethical research practices and regulatory requirements for drug development and testing.

Sanofi publishes sustainability reports and maintains ESG disclosure through its investor relations materials. The company's sustainability governance is integrated into its business strategy, with environmental impact reduction and access to medicines as key priorities.

The company's manufacturing footprint spans France, United States, Germany, Belgium, Canada, China, India, and Brazil, with environmental management systems in place across production facilities. Sanofi participates in industry initiatives to improve pharmaceutical manufacturing sustainability and reduce environmental impact.

Sanofi has received recognition for marketing effectiveness and innovation in the pharmaceutical industry.

In 2025, Sanofi won multiple awards at the Fierce Pharma Marketing Awards, demonstrating excellence in pharmaceutical marketing and patient engagement. The company's marketing campaigns for Dupixent and other products received industry recognition for effectiveness and creativity.

Sanofi maintains a strong position in pharmaceutical industry rankings, consistently appearing among the world's top 10 pharmaceutical companies by revenue. The company's R&D productivity and pipeline strength are recognized by industry analysts and rating agencies.

The company's innovation capabilities have been acknowledged through regulatory approvals and breakthrough therapy designations from major health authorities. In 2025, Sanofi obtained ten regulatory approvals across immunology, rare diseases, and other therapeutic areas, reflecting its research and development capabilities.

Sanofi has faced regulatory and legal challenges typical of large pharmaceutical companies operating in highly regulated markets globally.

In February 2026, Texas Attorney General Ken Paxton sued Sanofi for allegedly providing kickbacks to healthcare providers to boost drug prescriptions. The lawsuit alleges that Sanofi offers free nurses and insurance support services as an inducement to save physicians time and money, which Texas argues constitutes illegal bribing of providers to prescribe Sanofi medications over alternatives. The case is ongoing as of March 2026.

Like other major pharmaceutical companies, Sanofi faces ongoing scrutiny regarding drug pricing, particularly in the United States and Europe. The company's pricing strategies for specialty pharmaceuticals and rare disease treatments have been subject to public debate and regulatory review. In 2025, Sanofi reached an agreement with the US government to lower medicine costs while strengthening innovation, addressing some pricing concerns while maintaining R&D investment.

Sanofi has experienced pipeline setbacks typical of pharmaceutical development. In 2025, tolebrutinib in primary progressive multiple sclerosis did not meet the primary endpoint in phase 3 trials, representing a clinical development failure that required strategic adjustment.

The company underwent significant leadership changes in early 2026 when the Board of Directors decided not to renew CEO Paul Hudson's mandate after six years of leadership. Hudson's departure on February 17, 2026, and the appointment of Belén Garijo as new CEO effective April 29, 2026, represented a major governance transition that attracted industry attention.

Sanofi maintains transparency regarding legal proceedings and regulatory matters through its annual reports and investor communications. The company's financial disclosures include information on material litigation and regulatory challenges affecting its business operations.